P3.01-01 Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients
Yiqiang Wu(Guangdong General Hospital), Zhiyong Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), J. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), H. Zhang(Air Force Medical University), Y. Chen(Tongji Hospital), X. Zhang(Guangdong General Hospital), Zhangye Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), W. Liu(Sichuan University), Yongcun Cheng(Nanjing University of Information Science and Technology), Yu Hu(Hubei Cancer Hospital), Yi Lu(Shandong Provincial Hospital), G.X. Wu(Changzhou University)
Cited by 0
Related Papers
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Accuracy assessment of global barotropic ocean tide models
|Reviews of Geophysics|2014|553
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)
|Journal of Hematology & Oncology|2019|124
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
|Therapeutic Advances in Medical Oncology|2020|110